EGFR and non-small cell lung carcinoma: A subset of patients with recurrent or metastatic non-small cell lung cancer (NSCLC) were treated with either erlotinib (n = 25), an EGFR inhibitor, or sorafenib (n = 37), a VEGFR inhibitor, in a second-line setting.